The secondary analysis data from SYMPHONY I and II (Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post Acute Coronary Syndrome) were presented at the annual scientific sessions of the American Heart Association.
The oral glycoprotein inhibitor sibrafiban is no better than aspirin in secondary prevention of major ischemic events, even though it is the more potent inhibitor of platelet aggregation, reported Dr.